Aspirin and antiplatelet agent resistance: Implications for prevention of secondary stroke

CNS Drugs

Volumn 24, Issue 12, 2010, Pages 1027-1040

  Greer, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiplatelets, therapeutic use; Aspirin, therapeutic use; Clopidogrel, therapeutic use; Dipyridamole, therapeutic use; Prasugrel, therapeutic use; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PRASUGREL; THROMBOXANE B2;

DIABETES MELLITUS; DRUG TREATMENT FAILURE; HUMAN; IMPEDANCE AGGREGOMETRY; LABORATORY TEST; LIGHT TRANSMISSION AGGREGOMETRY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ASPIRIN; DIPYRIDAMOLE; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SECONDARY PREVENTION; STROKE; TICLOPIDINE;

EID: 78649338758     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11539160-0000000000-00000     Document Type: Review

References (86)

1. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 234S-64S
2. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008 May; 39: 1-6
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan; 324: 71-86
4. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovas- cular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004 Oct; 292: 1867-74
5. Lordkipanidze M, Pharand C, Schampaert E, et al. A com- parison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007 Jul; 28: 1702-8
6. Altman R, Luciardi HL, Muntaner J, et al. The antithrom- botic profile of aspirin: aspirin resistance or simply failure? Thromb J 2004 Jan; 2: 1 [online]. Available from URL: http://www.thrombosisjournal.com/content/2/1/1 [Accessed 2010 Sep 13]
7. U.S. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist 1998; 63: 56802-19
8. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 483S-512S
9. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs. 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991 Oct; 325: 1261-6
10. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007 May; 297: 2018-24
11. Diener HC, Bogousslavsky J, Brass LM, et al., MATCH In- vestigators. Aspirin and clopidogrel compared with clopido-grel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004 Jul; 364: 331-7
12. Yusuf S, Zhao F, Mehta SR, et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug; 345: 494-502
13. Bhatt DL, Fox KA, Hacke W, et al., CHARISMA Investi- gators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr; 354: 1706-17
14. Patrignani P, Renda G, Tacconelli S, et al. Response to pharmacodynamic interaction between aspirin and ibu-profen: a plausible mechanism of aspirin resistance. Clin Pharmacol Ther 2008 Jun; 83: 812-3
15. Adebayo GI, Williams J, Healy S. Aspirin esterase activity: evidence for skewed distribution in healthy volunteers. Eur J Intern Med 2007 Jul; 18: 299-303
16. Gresner P, Doln?k M, Waczul?kova I, et al. Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Biochim Biophys Acta 2006 Feb; 1760: 207-15
17. Cuisset T, Frere C, Quilici J, et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 2009 May; 157 (5): 889-93
18. Hamann GF, Weimar C, Glahn J, et al., German Stroke Data Bank. Adherence to secondary stroke prevention strategies: results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15 (4): 282-8
19. U.S. Food and Drug Administration. Concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/ Postmarket DrugSafetyInformationforPatientsandProviders/UCM161282. pdf [Accessed 2009 Dec 14]
20. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxy- genase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 Dec 20; 345 (25): 1809-17
21. Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006 Aug; 37 (8): 2153-8
22. Karha J, Rajagopal V, Kottke-Marchant K, et al. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006 May; 151: 976.e7-e11
23. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007 Mar; 5: 490-6
24. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004 Feb; 328: 477-9
25. Cheng G, Shan J, Xu G, et al. Relationship between en- dothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. J Clin Pharm Ther 2007 Jun; 32: 287-92
26. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspi- rin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008 Aug; 66: 222-32
27. Weber AA, Przytulski B, Schanz A, et al. Towards a defini- tion of aspirin resistance: a typological approach. Platelets 2002 Feb; 13: 37-40
28. Hohlfeld T, Weber AA, Junghans U, et al. Variable platelet response to aspirin in patients with ischemic stroke. Cere-brovasc Dis 2007; 24: 43-50
29. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 Apr; 105: 1650-5
30. Meen O, Brosstad F, Khiabani H, et al. No case of COX-1- related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2008; 68: 185-91
31. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007 Feb; 153: 175-81
32. Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 2007 May; 41: 737-41
33. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospec- tive, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003 Mar; 41: 961-5
34. Barnes GD, Li J, Kline-Rogers E, et al. Dual antiplatelet agent failure: a new syndrome or clinical nonentity? Am Heart J 2007 Oct; 154: 732-5
35. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non- responder status in patients with recurrent cerebral ische-mic attacks. J Neurol 2003 Jan; 250: 63-6
36. Martin CP, Talbert RL. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmaco-therapy 2005 Jul; 25: 942-53
37. Michelson AD, Cattaneo M, Eikelboom JW, et al., on be- half of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-11
38. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007 Jun; 115: 3156-64
39. Lau WC, Gurbel PA. Antiplatelet drug resistance and drug- drug interactions: role of cytochrome P450 3A4. Pharm Res 2006 Dec; 23: 2691-708
40. Ivandic BT, Giannitsis E, Schlick P, et al. Determination of aspirin responsiveness by use of whole blood platelet ag-gregometry. Clin Chem 2007 Apr; 53: 614-9
41. Poulsen TS, Jørgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients with an evolving acute myo-cardial infarction. Thromb Res 2007; 119: 555-62
42. Hobikoglu GF, Norgaz T, Aksu H, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetyl-salicylic acid therapy. Can J Cardiol 2007 Mar; 23: 201-6
43. Coleman JL, Wang JC, Simon DI. Determination of indivi- dual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point of Care 2004 Jun; 3: 77-82
44. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007 Jul; 120: 631-5
45. Seok JI, Joo IS, Yoon JH, et al. Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neuro-surg 2008 Feb; 110: 110-6
46. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005 May; 36: 1001-5
47. Chakroun T, Addad F, Abderazek F, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 2007; 121: 413-8
48. Dichiara J, Bliden KP, Tantry US, et al. Platelet function measured by VerifyNow® identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007 Sep; 18: 414-23
49. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004 Aug; 2: 1282-91
50. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Plate- let function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopido-grel treatment. Diabetes 2005 Aug; 54: 2430-5
51. Zimmermann N, Kurt M, Winter J, et al. Aspirin-induced platelet inhibition in patients undergoing cardiac surgery. Platelets 2007 Nov; 18: 528-34
52. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007 Mar; 5: 507-11
53. WiviottSD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004 Jun; 109: 3064-7
54. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007; 114-20
55. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007 Dec; 17: 1057-64
56. Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008 Aug; 84: 236-42
57. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006 Oct; 108: 2244-7
58. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contri- bution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006 Aug; 26: 1895-900
59. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009 Jan; 360: 354-62
60. Simon T, Verstuyft C, Mary-Krause M, et al., French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 Jan; 360: 363-75
61. Gilard M, Arnaud B, Cornily JC, et al. Influence of ome- prazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Ome-prazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 Jan; 51: 256-60
62. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008 Apr; 48: 475-84
63. U.S. Food and Drug Administration. Clopidogrel (mar- keted as Plavix) and omeprazole (marketed as Prilosec): drug interaction [online]. Available from URL: http:// www.fda.gov/Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm190848.htm [Accessed 2010 Sep 6]
64. Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 2009; 104: 227-33
65. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and 2 risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008 Feb; 29: 281-5
66. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-34
67. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003 Jun; 107: 2908-13
68. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel re- sistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 Jun; 109: 3171-5
69. Bonello L. Platelet monitoring of clopidogrel response using VASP phosphorylation index decreases rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. American College of Cardiology Scientific Sessions/i2 Summit-SCAI Annual Meeting; 2008 Mar 29; Chicago (IL).
70. Late breaking clinical trials I [online]. Available from URL: http://www.the heart.org/article/850995.do [Accessed 2010 Sep 6]
71. Pride YB, Wiviott SD, Buros JL, et al., TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRI-TON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J 2009 Sep; 158 (3): e21-6
72. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008 Dec 9; 52 (24): 1968-77
73. Eisert WG. Near-field amplification of antithrombotic ef- fects of dipyridamole through vessel wall cells. Neurology 2001; 57 (5 Suppl. 2): S20-3
74. Derendorf H, Estes K. The significance of optimised for- mulation for dipyridamole in stroke risk reduction. Eur Neurol Dis 2007; (2): 21-3
75. Serebruany V, Malinin A, Ziai W, et al. Dipyridamole de- creases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin non-responsiveness. Cerebrovasc Dis 2006; 21: 98-105
76. Aktas B, Utz A, Hoenig-Liedl P, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003 Mar; 34: 764-9
77. Cayla G, Macia JC, Rabesandratana H, et al. Flow cyto- metric assessment of vasodilator-stimulated phosphopro-tein: prognostic value of recurrent cardiovascular events after acute coronary syndromes. Arch Cardiovasc Dis 2008 Nov-Dec; 101: 743-51
78. ESPRIT Study Group, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral is-chaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006 May; 367: 1665-73
79. Diener HC, Darius H, Bertrand-Hardy JM, et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001 Apr; 55: 162-3
80. Patel D, Moonis M. Clinical implications of aspirin resis- tance. Expert Rev Cardiovasc Ther 2007 Sep; 5: 969-75
81. Hirsh J, Guyatt G, Albers GW, et al., American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 Jun; 133 (6 Suppl.): 110S-2S
82. Takahashi S, Ushida M, Komine R, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007; 119: 517-24
83. Frelinger 3rd AL, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adeno-sine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006 Jun; 113: 2888-96
84. Dropinski J, Jakiela B, Sanak M, et al. The additive anti- platelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007 Jul; 98: 201-9
85. Tirnaksiz E, Pamukcu B, Oflaz H, et al. Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2009 Jan; 27: 2724-8
86. Cannon CP, Harrington RA, James S, et al., PLATelet in- hibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010 Jan 23; 375 (9711): 283-93